Evidence map›Paper›PMID 38201645›Full record

ArticleCancers2024

New

Tomasz Poplawski, Grzegorz Galita, Joanna Sarnik, Anna Macieja, Roman Bielski, Donald E Mencer, Zbigniew J Witczak

Abstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tomasz PoplawskiDepartment of Pharmaceutical Microbiology and Biochemistry, Medical University, 92-215 Lodz, Poland.ORCID 0000-0003-2300-7339
Grzegorz GalitaDepartment of Clinical Chemistry and Biochemistry, Medical University, 92-215 Lodz, Poland.ORCID 0000-0002-1559-2796
Joanna SarnikDepartment of Rheumatology, Medical University, 90-050 Lodz, Poland.ORCID 0000-0002-7343-8551
Anna MaciejaDepartment of Pharmaceutical Microbiology and Biochemistry, Medical University, 92-215 Lodz, Poland.ORCID 0000-0001-6056-7808
Roman BielskiDepartment of Pharmaceutical Sciences, Nesbitt School of Pharmacy, Wilkes University, 84 W. South Street, Wilkes-Barre, PA 18766, USA.ORCID 0000-0003-1613-6917
Donald E MencerDepartment of Chemistry and Biochemistry, Wilkes University, 84 W. South Street, Wilkes-Barre, PA 18766, USA.ORCID 0000-0002-0341-8539
Zbigniew J WitczakDepartment of Pharmaceutical Sciences, Nesbitt School of Pharmacy, Wilkes University, 84 W. South Street, Wilkes-Barre, PA 18766, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The conjugate N-adducts of thio-1,3,4-diazole and 2-thiazoline with levoglucosenone were synthesized via a stereoselective, base-catalyzed conjugate N-Michael addition to levoglucosenone at C-4. Structural assignments were established using 1H and 13C NMR analysis, and X-ray single-crystal analysis for one of the compounds. The biological properties of the novel compounds were tested on a cell model. Cytotoxicity was analyzed via colorimetric assay. Two distinct types of cell death, apoptosis and necrosis, were analyzed by determining the phosphatidylserine levels from the outer leaflet of the plasma membrane, caspase activation, and lactate dehydrogenase release. We also evaluated DNA damage using an alkaline comet assay. The level of oxidative stress was measured with a modified comet assay and an H2DCFDA probe. The thio-1,3,4-diazole adduct (FCP23) and the 2-thiazoline adduct (FCP26) exhibit similar cytotoxicity values for cancer cells (ovarian (A2780), breast (MCF-7), cervix (HeLa), colon (LoVo), and brain (MO59J and MO59K)), but their mechanism of action is drastically different. While FCP23 induces oxidative stress, DNA damage, and necrosis, FCP26 induces apoptosis through caspase activation.

Indexed as

apoptosisDNA damagelevoglucosenonethiadiazolethiazoline

Identifiers

PMID38201645
PMCPMC10777969

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.